Moderna to Set Up mRNA Vaccine Manufacturing Plant in Kenya

Moderna is establishing a messenger RNA (mRNA) production facility in Kenya, its first such plant on the continent.

The Cambridge, Mass.-based drugmaker plans to invest $500 million in setting up the new plant and projects that, once fully operational, the facility will be able to produce up to 500 million mRNA vaccine doses a year.

Moderna said the facility will focus on drug substance manufacturing for the African continent and could also include fill/finish and packaging capabilities down the line. The company hopes to begin filling COVID-19 vaccine doses in the plant as early as 2023.